Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Beats Estimates By $0.07 EPS

by · The Cerbat Gem

Coya Therapeutics (NASDAQ:COYA – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07, FiscalAI reports. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.

Coya Therapeutics Stock Performance

Shares of NASDAQ:COYA traded up $0.05 during mid-day trading on Tuesday, hitting $4.23. 366,751 shares of the company traded hands, compared to its average volume of 184,783. The firm has a market cap of $99.24 million, a P/E ratio of -3.33 and a beta of 0.55. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The firm’s 50 day simple moving average is $4.39 and its 200 day simple moving average is $5.09.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. JPMorgan Chase & Co. purchased a new stake in shares of Coya Therapeutics during the 3rd quarter valued at about $28,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $47,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $66,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Coya Therapeutics during the 2nd quarter worth approximately $119,000. Finally, Millennium Management LLC purchased a new stake in Coya Therapeutics during the 4th quarter worth approximately $121,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. D. Boral Capital restated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Friday, April 10th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, March 23rd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

View Our Latest Stock Analysis on COYA

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

Featured Stories